Sources of bias in the economic analysis of new drugs
Prendergast, M.M.
JAMA 283(11): 1424
2000
ISSN/ISBN: 0098-7484 PMID: 10732927 Document Number: 524936
Document emailed within 1 workday
Related Documents
Le Pen, C. 2000: Sources of bias in the economic analysis of new drugs JAMA 283(11): 1423-1424Dussaucy, A.; Viel, J.F.; Mulin, B.; Euvrard, J. 1994: The framework Prospective Payment Information Systems: bias, sources of errors and consequences Revue d'Epidemiologie et de Sante Publique 42(4): 345-358
Soto Alvarez, J.; Fernández Cano, P. 1997: Analysis of the economic evaluation of drugs in primary care: concept, methodology and practical applications Atencion Primaria 20(10): 563-568
Moultrie, T.A.; Dorrington, R. 2008: Sources of error and bias in methods of fertility estimation contingent on the P/F ratio in a time of declining fertility and rising mortality Demographic Research 19: 1635-1662
Moultrie, T.A.; Dorrington, R. 2008: Sources of error and bias in methods of fertility estimation contingent on the P/F ratio in a time of declining fertility and rising mortality Demographic Research 19: 1635-1662
Sugita, M.; Miyakawa, M. 2010: Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example Environmental Health and Preventive Medicine 15(4): 244-251
Sugita, M.; Miyakawa, M. 2010: Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example Environmental Health and Preventive Medicine 15(4): 244-251
Jones, K. 2020: Interpretations of Gender Bias in the Technology Sector: Does Bias Impact Organizational Attractiveness? The International Journal of Diversity in Organizations, Communities, and Nations: Annual Review 19(1): 19-35
Rooney, P.J.; Kean, W.F. 1987: Reinforcement of bias in the medical literature: nonsteroidal anti-inflammatory drugs and the stomach--a case in point British Journal of Rheumatology 26(3): 231-233
Vaara, M. 1998: Sources for antibacterial drugs are not drying up Duodecim; Laaketieteellinen Aikakauskirja 114(7): 615; 617
Weiss, R.B. 1997: New sources and new antitumor drugs in development Seminars in Oncology 24(2): 153-155
Lash, T.L.; Ahern, T.P. 2012: Bias analysis to guide new data collection International Journal of Biostatistics 8(2)
Biljana, M.; Jelena, M.; Branislav, J.; Milorad, R. 1999: Bias in meta-analysis and funnel plot asymmetry Studies in Health Technology and Informatics 68: 323-328
Gibson, J.; Rozelle, S. 2004: Is it Better to be a Boy? a Disaggregated Outlay Equivalent Analysis of Gender Bias in Papua new Guinea Journal of Development Studies 40(4): 115-136
Allen, L.V. 2006: Basics of compounding for hazardous drugs, part 2: regulation and sources of contamination International Journal of Pharmaceutical Compounding 10(6): 446-448
Grigorescu, E.; Gaiţă, G. 1974: Macromolecules of plant origin as sources of raw material in semisynthesis of drugs. I. Biogenesis of lignin Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 78(1): 129-135
Tiewcharoen, S.; Junnu, V.; Suvoutho, S. 2003: Effect of antifungal drugs on pathogenic Naegleria spp isolated from natural water sources Journal of the Medical Association of Thailand 86(9): 876-882
Huddle, D.L. 1967: The Brazilian Industrialization. Sources, Patterns, and Policy Mix Industrialization and Economic Development in Brazil Werner Baer Economic Development and Cultural Change 15(4): 472-479
Aigrain, P. 1996: World vitivinicultural economic outlook. Report of the Group 'Economic analysis and outlook', March 1996 Bulletin de l' OIV 69(781/782): 334-349
Evans, W.K.; Coyle, D.; Gafni, A.; Walker, H. 2003: Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis Chronic diseases in Canada 24(4): 102-107